Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Nov 10, 7:23 PMCumberland transformed by $100M Apotex sale, Q3 net income $77.8M as it pivots to ifetroban DMD NDA
Index
-
Market Cap
79.56M
Enterprise Value
80.08M
Income
-10.92M
Sales
31.27M
Book/sh
1.16
Cash/sh
0.26
Employees
93
IPO
Aug 11, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
2.54
P/B
4.56
P/C
20.61
P/FCF
117.00
EV/EBITDA
-
EV/Sales
2.56
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
0.27
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
-0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
20.68% 2.82%
Sales past 3/5Y
1.95% 3.52%
EPS Y/Y TTM
-244.92%
Sales Y/Y TTM
-25.68%
EPS Q/Q
-476.57%
Sales Q/Q
-98.46%
Insider Own
41.60%
Insider Trans
0.00%
Inst Own
20.88%
Inst Trans
-6.64%
ROA
-14.91%
ROE
-42.92%
ROIC
-50.43%
Gross Margin
86.22%
Oper. Margin
-29.58%
Profit Margin
-34.92%
SMA20
-9.16%
SMA50
-19.99%
SMA200
9.14%
Trades
Shs Outstand
14.98M
Shs Float
8.75M
52W High
9.28 -42.78%
52W Low
1.43 270.14%
Volatility
12.39% 14.85%
ATR (14)
0.65
RSI (14)
44.04
Beta
0.28
Rel Volume
0.04
Avg Volume
92.45K
Volume
162
Perf Week
19.59%
Perf Month
-25.94%
Perf Quarter
-32.78%
Perf Half Y
41.19%
Perf YTD
72.05%
Perf Year
242.38%
Perf 3Y
286.87%
Perf 5Y
154.56%
Perf 10Y
37.50%
Prev Close
5.30
Price
5.31
Change %
0.19%
Consensus
Strong Buy
Avg. Price Target
$9.75
Implied Upside
+83.6%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2012Reiterated
UBS logoUUBS
Neutral$6.50 → $5-5.8%
Feb 01, 2011Reiterated
UBS logoUUBS
Neutral$8 → $6.50+22.4%
Dec 16, 2010Downgrade
UBS logoUUBS
Buy → Neutral$10 → $8+50.7%
Aug 17, 2010Reiterated
UBS logoUUBS
Buy$11 → $10+88.3%
Aug 17, 2010Reiterated
MMorgan Joseph
Buy$15 → $10+88.3%
Aug 17, 2010Downgrade
JEF logoJJefferies
Buy → Hold$13 → $5.50+3.6%
May 14, 2010Reiterated
MMorgan Joseph
Buy$21 → $15+182.5%
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
FounderMr. A. J. Kazimi MBA
Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.
Vice President of Organizational DevelopmentMr. Todd M. Anthony
Managing Director of Banking & Investor RelationsMr. Adam S. Mostafa